Table 2 Comparison of SVR rates between two PEG-IFN groups according to categorized variables
Genotype 1 | PEG-IFN alfa-2a | PEG-IFN alfa-2b | P* |
|---|---|---|---|
(n=416) | (n=254) | (n=162) | |
SVR, n (%) | 158 (62.2) | 104 (64.2) | 0.76 |
Age, n (%) | |||
≤50 years (n=212) | 88/133 (66.2) | 61//79 (77.2) | 0.12 |
>50 years (n=204) | 70/121 (57.9) | 43/83 (51.8) | 0.47 |
HCV RNA (IU/mL), n (%) | |||
≤7×105(n=149) | 76/117 (65.0) | 46/67 (68.7) | 0.63 |
>7×105(n=232) | 82/137 (59.9) | 58/95 (61.1) | 0.89 |
Liver fibrosis, n (%) † | |||
F 0–2 (n=80) | 48/62 (77.4) | 11/18 (61.1) | 0.22 |
F 3–4 (n=49) | 18/43 (41.9) | 4/6 (66.7) | 0.39 |
Genotype 2/3 | PEG-IFN alfa-2a | PEG-IFN alfa-2b | 0.29 |
(n=235) | (n=141) | (n=94) | |
SVR, n (%) | 112 (79.4) | 75 (79.8) | 1.00 |
Age, n (%) | |||
≤50 years (n=125) | 71/80 (88.8) | 38/45 (84.4) | 0.58 |
>50 years(n=110) | 41/61 (67.2) | 37/49 (75.5) | 0.40 |
HCV RNA (IU/mL), n (%) | |||
≤7×105 (n=137) | 63/81(77.8) | 49/56 (87.5) | 0.18 |
>7×105 (n=98) | 49/60 (81.7) | 26/38 (68.4) | 0.15 |
Liver fibrosis, n (%) ‡ | |||
F 0–2 (n=59) | 42/51 (82.4) | 7/8 (87.5) | 1.00 |
F 3–4 (n=15) | 7/10 (70.0) | 3/5 (60.0) | 1.00 |